Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer”

40 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 40 results

Testing effectiveness (Phase 2)UnknownNCT04895930
What this trial is testing

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
Shanghai Chest Hospital 40
Testing effectiveness (Phase 2)Study completedNCT01250119
What this trial is testing

Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 688
Testing effectiveness (Phase 2)Active Not RecruitingNCT05801029
What this trial is testing

Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Large-scale testing (Phase 3)Active Not RecruitingNCT04035486
What this trial is testing

Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 587
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06982924
What this trial is testing

A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

Who this might be right for
EGFR Mutation Positive Advanced Non Small Cell Lung CancerPD-L1 Positive
Shanghai Chest Hospital 136
Large-scale testing (Phase 3)Active Not RecruitingNCT04143607
What this trial is testing

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 337
Large-scale testing (Phase 3)Study completedNCT02151981
What this trial is testing

AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Anticancer Treatment
AstraZeneca 421
Testing effectiveness (Phase 2)Active Not RecruitingNCT03778229
What this trial is testing

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Who this might be right for
Carcinoma
AstraZeneca 367
Testing effectiveness (Phase 2)UnknownNCT03502850
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 507
Large-scale testing (Phase 3)Active Not RecruitingNCT04765059
What this trial is testing

Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 98
Testing effectiveness (Phase 2)UnknownNCT03460275
What this trial is testing

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 100
Large-scale testing (Phase 3)Study completedNCT02454933
What this trial is testing

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

Who this might be right for
Locally Advanced or Metastatic EGFR T790M+ NSCLC
AstraZeneca 29
Large-scale testing (Phase 3)Active Not RecruitingNCT03787992
What this trial is testing

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 358
Not applicableApproved For MarketingNCT04829422
What this trial is testing

Early Access Program of Lazertinib in Republic of Korea

Who this might be right for
Lung Cancer
Yuhan Corporation
Testing effectiveness (Phase 2)Study completedNCT01982955
What this trial is testing

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Who this might be right for
Non-small Cell Lung Cancer
Merck KGaA, Darmstadt, Germany 88
Large-scale testing (Phase 3)Study completedNCT04206072
What this trial is testing

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Who this might be right for
Non-Small Cell Lung CancerEGFR Gene Mutation
Betta Pharmaceuticals Co., Ltd. 362
Large-scale testing (Phase 3)Study completedNCT02296125
What this trial is testing

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AstraZeneca 674
Testing effectiveness (Phase 2)Study completedNCT04184921
What this trial is testing

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

Who this might be right for
Lung Cancer Non-small Cell Stage IV
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 216
Large-scale testing (Phase 3)Active Not RecruitingNCT04248829
What this trial is testing

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Who this might be right for
Non-Small Cell Lung Cancer
Yuhan Corporation 393
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 764
Load More Results